Literature DB >> 18302944

DNp73 a matter of cancer: mechanisms and clinical implications.

Sven Buhlmann1, Brigitte M Pützer.   

Abstract

The p53 family proteins carry on a wide spectrum of biological functions from differentiation, cell cycle arrest, apoptosis, and chemosensitivity of tumors. NH2-terminally truncated p73 (referred to as DNp73) acts as a potent inhibitor of all these tumor suppressor properties, implying that it has oncogenic functions in human tumorigenesis. This was favored by the observation that high DNp73 expression levels in a variety of cancers are associated with adverse clinico-pathological characteristics and the response failure to chemotherapy. The actual challenge is the deciphering of the molecular mechanisms by which DNp73 promotes malignancy and to unravel the regulatory pathways for controlling TP73 isoform expression. This review is focused on recent findings leaving no doubt that N-terminally truncated p73 proteins are operative during oncogenesis, thus underscoring its significance as a marker for disease severity in patients and as target for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18302944     DOI: 10.1016/j.bbcan.2008.01.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  26 in total

1.  Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors.

Authors:  A E Vilgelm; S-M Hong; M K Washington; J Wei; H Chen; W El-Rifai; A Zaika
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

2.  IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DeltaNp73alpha phosphorylation and stabilization.

Authors:  Rosita Accardi; Mariafrancesca Scalise; Tarik Gheit; Ishraq Hussain; Jiping Yue; Christine Carreira; Agnese Collino; Cesare Indiveri; Lutz Gissmann; Bakary S Sylla; Massimo Tommasino
Journal:  Mol Cell Biol       Date:  2011-04-11       Impact factor: 4.272

3.  Oncoprotein E7 from beta human papillomavirus 38 induces formation of an inhibitory complex for a subset of p53-regulated promoters.

Authors:  Djamel Saidj; Marie-Pierre Cros; Hector Hernandez-Vargas; Francesca Guarino; Bakary S Sylla; Massimo Tommasino; Rosita Accardi
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

4.  High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.

Authors:  Antonio R Lucena-Araujo; Haesook T Kim; Carolina Thomé; Rafael H Jacomo; Raul A Melo; Rosane Bittencourt; Ricardo Pasquini; Katia Pagnano; Ana Beatriz F Glória; Maria de Lourdes Chauffaille; Melina Athayde; Carlos S Chiattone; Ingrid Mito; Rodrigo Bendlin; Carmino Souza; Cristina Bortolheiro; Juan L Coelho-Silva; Stanley L Schrier; Martin S Tallman; David Grimwade; Arnold Ganser; Nancy Berliner; Raul C Ribeiro; Francesco Lo-Coco; Bob Löwenberg; Miguel A Sanz; Eduardo M Rego
Journal:  Blood       Date:  2015-10-01       Impact factor: 22.113

5.  {Delta}Np73{beta} puts the brakes on DNA repair.

Authors:  Emma Vernersson-Lindahl; Alea A Mills
Journal:  Genes Dev       Date:  2010-03-15       Impact factor: 11.361

Review 6.  A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Authors:  D Engelmann; C Meier; V Alla; B M Pützer
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

7.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

Review 8.  Mechanisms, function and clinical applications of DNp73.

Authors:  Cuixia Di; Lina Yang; Hong Zhang; Xiaofei Ma; Xin Zhang; Chao Sun; Hongyan Li; Shuai Xu; Lizhe An; Xun Li; Zhongtian Bai
Journal:  Cell Cycle       Date:  2013-06-13       Impact factor: 4.534

9.  Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs.

Authors:  W Bunjobpol; I Dulloo; K Igarashi; N Concin; K Matsuo; K Sabapathy
Journal:  Cell Death Differ       Date:  2014-04-11       Impact factor: 15.828

10.  Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.

Authors:  Stephan Emmrich; Weiwei Wang; Katja John; Wenzhong Li; Brigitte M Pützer
Journal:  Mol Cancer       Date:  2009-08-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.